Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells $554,110.15 in Stock

Posted by Andrew Walz on Jul 26th, 2024

Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) EVP Valerie Morisset sold 69,005 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $8.03, for a total value of $554,110.15. Following the completion of the transaction, the executive vice president now owns 31,317 shares in the company, valued at approximately $251,475.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Valerie Morisset also recently made the following trade(s):

On Friday, July 19th, Valerie Morisset sold 60,201 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.21, for a total value of $434,049.21.
On Wednesday, July 17th, Valerie Morisset sold 3,207 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.91, for a total value of $22,160.37.
On Monday, July 15th, Valerie Morisset sold 42,377 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $297,062.77.
On Thursday, July 11th, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.11, for a total value of $355,500.00.
On Tuesday, July 9th, Valerie Morisset sold 5,931 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.66, for a total value of $39,500.46.
On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $87,134.52.
On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.76, for a total value of $338,000.00.

Eliem Therapeutics Trading Up 2.7 %

Shares of ELYM opened at $8.90 on Friday. The company has a market capitalization of $264.78 million, a price-to-earnings ratio of -16.79 and a beta of -0.33. The stock has a 50 day moving average of $7.70 and a 200 day moving average of $5.12. Eliem Therapeutics, Inc. has a 12 month low of $2.35 and a 12 month high of $11.55.

Eliem Therapeutics (NASDAQ:ELYM – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.06) EPS for the quarter.

Institutional Trading of Eliem Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC purchased a new stake in Eliem Therapeutics in the fourth quarter worth $37,000. Bank of New York Mellon Corp purchased a new stake in Eliem Therapeutics in the second quarter worth $134,000. Finally, BML Capital Management LLC increased its position in Eliem Therapeutics by 12.5% in the fourth quarter. BML Capital Management LLC now owns 2,180,000 shares of the company’s stock worth $5,886,000 after buying an additional 241,737 shares during the last quarter. 69.76% of the stock is owned by hedge funds and other institutional investors.

Eliem Therapeutics Company Profile

(Get Free Report)

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.